RecruitingNot ApplicableNCT07680244

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

Sponsor

Carl Zeiss Meditec-Dublin CoCe

Enrollment

400 participants

Start Date

May 23, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called PathFinder 1.0 on CIRRUS HD-OCT for people with dry age-related macular degeneration, epiretinal membrane, and other related conditions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEPathFinder 1.0 on CIRRUS HD-OCT

Participants undergo standard OCT imaging on CIRRUS HD-OCT systems, and the investigational PathFinder software analyzes the images for macular abnormalities without influencing clinical care.